Muurling, Marijn http://orcid.org/0000-0001-9397-4602
de Boer, Casper
Vairavan, Srinivasan http://orcid.org/0000-0001-7975-8436
Harms, Robbert L.
Chadha, Antonella Santuccione
Tarnanas, Ioannis http://orcid.org/0000-0003-4069-6551
Luis, Estefania Vilarino
Religa, Dorota
Gjestsen, Martha Therese
Galluzzi, Samantha
Ibarria Sala, Marta
Koychev, Ivan
Hausner, Lucrezia
Gkioka, Mara
Aarsland, Dag
Visser, Pieter Jelle
Brem, Anna-Katharine http://orcid.org/0000-0003-0295-6834
Funding for this research was provided by:
Innovative Medicines Initiative (806999, 806999, 806999, 806999, 806999, 806999, 806999, 806999, 806999)
National Institute of Health Research (personal award and Oxford Health Biomedical Research Centre) and the Medical Research Council
Article History
Received: 17 May 2023
Accepted: 29 November 2023
First Online: 18 December 2023
Competing interests
: R.L.H., A.S.C. and I.T. are employees of Altoida Inc. and declare no non-financial competing interests. S.V. is an employee of Janssen Pharmaceutical NV and may hold stock options or shares in the company, but has no non-financial competing interests. D.A. has received research support and/or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals, Biogen, and GE Health, and served as a paid consultant for H. Lundbeck, Eisai, Heptares, Mentis Cura, and Roche Diagnostics, but declares no non-financial competing interests. S.G. declares support for this work through the Italian Ministry of Health (Ricerca Corrente). All other authors declare no financial or non-financial competing interests.